Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. Combining
monoclonal antibody therapy with chemotherapy may kill more cancer cells.
PURPOSE: Randomized phase II trial to compare the effectiveness of fludarabine given with or
without monoclonal antibody therapy followed by monoclonal antibody therapy alone in treating
patients who have untreated B-cell chronic lymphocytic leukemia.